Oestrogen and Visceral Fat: Menopause Explained

Oestrogen and visceral fat are closely linked, particularly during and after the menopause. Oestrogen plays a key role in directing where the body stores fat, favouring peripheral depots such as the hips and thighs over the deeper abdominal compartment. When oestrogen levels fall during the menopause, this protective effect diminishes and visceral fat tends to accumulate, raising the risk of cardiovascular disease, type 2 diabetes and other metabolic conditions. Understanding this relationship can help women and clinicians make informed decisions about lifestyle changes, monitoring and whether treatments such as HRT may be appropriate.

How does oestrogen affect where your body stores fat?

Oestrogen promotes fat storage in peripheral subcutaneous sites such as the hips and thighs by acting on adipose tissue receptors, reducing fat deposition in the deeper visceral abdominal compartment.

Oestrogen is associated with directing fat storage towards the hips, thighs and buttocks, and away from the abdomen, which is why women of reproductive age tend to carry fat in a pear-shaped distribution. This effect is thought to be mediated through oestrogen receptors found in adipose tissue, particularly in subcutaneous fat depots. When oestrogen binds to these receptors, it appears to promote the preferential uptake and storage of fatty acids in peripheral, subcutaneous sites rather than in the deeper visceral compartment surrounding the abdominal organs. Genetic, dietary and physical-activity factors also contribute to individual fat distribution patterns alongside hormonal influences.

Oestrogen also appears to influence the activity of lipoprotein lipase, an enzyme that regulates fat uptake into cells, and may modulate the release of adipokines, hormones secreted by fat tissue that affect metabolism, inflammation and insulin sensitivity.^[1][18] Higher oestrogen levels are associated with greater insulin sensitivity and a more favourable metabolic profile overall, though the precise mechanisms continue to be studied.

Beyond fat distribution, oestrogen may play a role in regulating appetite and energy expenditure through its effects on the hypothalamus. Research suggests that oestrogen signalling in the brain is associated with appetite regulation and metabolic function.^[6][7] When oestrogen levels are stable, these mechanisms may work together to support a body composition that is metabolically less harmful than one dominated by visceral fat.

Why does visceral fat increase during the menopause?

Falling oestrogen during the menopause removes the hormonal signal that directed fat away from the abdomen, causing a shift to central visceral fat accumulation even without overall weight gain.

Visceral fat tends to increase during the menopause primarily because falling oestrogen levels remove the hormonal signal that previously directed fat storage away from the abdomen. As ovarian function declines, the body's fat distribution shifts from a peripheral, subcutaneous pattern to a more central, visceral one, even in women whose total body weight remains relatively stable. Imaging studies using DXA and CT scanning have shown that this redistribution can occur independently of weight gain, meaning that a woman may notice a change in waist circumference without a significant change on the scales.^[8][10]

The decline in oestrogen is also associated with reduced insulin sensitivity, making cells less responsive to insulin and increasing the likelihood that circulating glucose and fatty acids are deposited as visceral fat. Simultaneously, cortisol, a stress hormone associated with abdominal fat accumulation, may become relatively more influential as oestrogen levels fall, though the evidence for a direct counterbalancing relationship is not fully established. Sleep disturbances, which are common during the perimenopause and menopause, can further elevate cortisol and disrupt appetite-regulating hormones such as leptin and ghrelin.^[10]

Age-related changes in muscle mass, known as sarcopenia, compound the problem. Reduced muscle tissue lowers the basal metabolic rate, meaning fewer calories are burned at rest. This combination of hormonal change, altered metabolism and reduced lean mass creates conditions in which visceral fat accumulates more readily. It is important to note that structured diet and exercise can meaningfully reduce visceral fat in postmenopausal women, and lifestyle interventions remain a cornerstone of management with or without hormonal treatment.

What health risks are linked to belly fat after the menopause?

Excess visceral fat after the menopause significantly raises the risk of cardiovascular disease, type 2 diabetes, MASLD and certain cancers, due to its release of pro-inflammatory cytokines into the portal circulation.

Excess visceral fat after the menopause is associated with a significantly increased risk of cardiovascular disease, type 2 diabetes, and certain cancers, including breast and endometrial cancer. Unlike subcutaneous fat, which sits beneath the skin, visceral fat is metabolically active and surrounds vital organs including the liver, pancreas and intestines. It releases pro-inflammatory cytokines and free fatty acids directly into the portal circulation, contributing to systemic inflammation, dyslipidaemia and insulin resistance.^[2]

Cardiovascular risk is of particular concern. Before the menopause, oestrogen is associated with a degree of cardiovascular protection, partly by supporting a favourable lipid profile and arterial flexibility. After the menopause, this protection diminishes, and the accumulation of visceral fat may accelerate the development of atherosclerosis. Current NICE guidance on measuring overweight and obesity risk recommends using BMI alongside waist-to-height ratio as a clinically meaningful measure of risk; a waist-to-height ratio above 0.5 is generally considered to indicate increased risk. Women who notice a significant increase in waist circumference during or after the menopause should discuss this with their GP, as it may warrant assessment of cardiovascular risk factors, blood glucose and lipid levels. The NHS Health Check programme, available to adults aged 40 to 74 without pre-existing relevant conditions, includes assessment of these risk factors.^[13]

Visceral fat is also strongly linked to metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease), obstructive sleep apnoea and hypertension.^[19][20] The inflammatory environment it creates may contribute to joint pain and has been studied in relation to cognitive health, though the evidence base for the latter continues to evolve.

Can HRT help reduce visceral fat in menopausal women?

Oestrogen-containing HRT may attenuate central fat redistribution in menopausal women, but it is not a weight-loss treatment and should be considered alongside lifestyle modification for appropriate candidates.

Hormone replacement therapy (HRT) may help attenuate the accumulation of visceral fat in menopausal women, though it is not a weight-loss treatment and its effects on body composition are modest. Clinical studies have shown that oestrogen-containing HRT is associated with a reduction in central fat redistribution compared with no treatment, and some evidence suggests it may help preserve lean muscle mass.^[23][9] The mechanism reflects the same pathways described earlier: restoring oestrogen signalling may help redirect fat storage away from visceral depots and support insulin sensitivity.

NICE guideline NG23 on menopause recommends that HRT should be offered to women with menopausal symptoms after a discussion of the benefits and risks, and that the decision should be individualised.^[14] HRT is not recommended solely for the purpose of reducing visceral fat, but improvements in body composition may be a secondary benefit for women who are already appropriate candidates.

There are important safety considerations. Women who have an intact uterus require a progestogen alongside systemic oestrogen to protect the endometrium from hyperplasia; oestrogen alone is not appropriate in this group.^[14] HRT is generally not recommended for women with a current or recent oestrogen-dependent cancer (unless under specialist guidance), active or past venous thromboembolism (VTE), undiagnosed vaginal bleeding, or active liver disease, among other contraindications. The type, dose and route of HRT matter: transdermal oestrogen is generally preferred for women with higher cardiovascular or VTE risk, as it avoids the first-pass hepatic effect associated with oral preparations and carries a lower associated VTE and stroke risk. HRT is not a contraceptive, and perimenopausal women who require contraception should discuss appropriate options with their clinician. The NICE HRT patient decision aid provides a balanced summary of absolute risks and benefits to support shared decision-making.

Women considering HRT should have a thorough clinical assessment, including a review of personal and family medical history. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online menopause consultations, with prescriber review and pharmacist support, where HRT may be one option a prescriber considers if it is clinically appropriate. If you experience suspected side effects from any medicine, you can report them via the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk. HRT works best as part of a broader approach that includes lifestyle modification, and its effects on visceral fat are likely to be most meaningful when combined with regular physical activity and a balanced diet.

Lifestyle changes that can help reduce visceral fat alongside HRT

Resistance training, aerobic exercise, a Mediterranean-style diet, adequate sleep and stress management are all evidence-based strategies that can meaningfully reduce visceral fat in menopausal women.

Regular physical activity is one of the most effective strategies for reducing visceral fat in menopausal women, and its benefits are additive to any effect from HRT. Both aerobic exercise and resistance training contribute, but evidence suggests that resistance training is particularly valuable during and after the menopause because it preserves and builds lean muscle mass, which in turn supports a higher resting metabolic rate. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, or 75 minutes of vigorous-intensity activity, alongside muscle-strengthening activities on two or more days per week.^[15][16] Those who are less active or have comorbidities should aim to build up gradually and may wish to seek advice from their GP or a physiotherapist before starting a new exercise programme.

Dietary changes also play a central role. A diet rich in vegetables, legumes, wholegrains, lean protein and healthy fats, broadly consistent with a Mediterranean-style pattern and aligned with the NHS Eatwell Guide, is associated with lower visceral fat and reduced cardiovascular risk. Reducing ultra-processed foods, refined carbohydrates and added sugars helps to manage insulin levels and limit the conditions that favour visceral fat deposition. Adequate protein intake is particularly important during the menopause to support muscle retention.

Sleep quality and stress management are often overlooked but clinically relevant. Poor sleep raises cortisol and disrupts appetite hormones, both of which are associated with abdominal fat accumulation. Cognitive behavioural therapy for insomnia (CBT-I) is recommended by NICE as a first-line treatment for sleep difficulties and may be available through NHS Talking Therapies, though access varies by region. Mindfulness-based approaches and structured relaxation techniques may also help manage stress.

Key practical steps include:

• Aim for 150 minutes of moderate aerobic activity weekly (or 75 minutes of vigorous activity), such as brisk walking, swimming or cycling, building up gradually if needed

• Include resistance training at least twice a week to preserve muscle mass

• Follow a Mediterranean-style diet in line with the NHS Eatwell Guide, limiting ultra-processed foods and refined sugars

• Prioritise sleep, aiming for 7 to 9 hours per night, and seek support for persistent insomnia

• Manage stress through evidence-based techniques such as mindfulness or CBT

• Monitor your waist-to-height ratio (a ratio above 0.5 indicates increased risk) and discuss significant changes with your GP

Frequently Asked Questions